Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc. Earnings Recaps

INO Health Care 2 recaps
Q1 2026 May 14, 2026

Shares declined 5.0% as investors reacted negatively to growing regulatory uncertainty and a cautious outlook for INO-3107’s accelerated approval, with no clear resolution on the FDA’s eligibility concerns or confirmatory trial protocol. The lack of concrete progress on these key regulatory milestones heightened execution risk and weighed on confidence.

Key takeaways
  • FDA completed mid-cycle review of the INO-3107 biologics license application (BLA) with no new significant issues, but an unresolved question remains regarding eligibility for accelerated approval.
  • An informal FDA meeting to discuss the eligibility concern, initially agreed upon, has yet to be scheduled, prolonging regulatory uncertainty.
  • Updated protocol for the required confirmatory trial has been submitted, but feedback is still pending, delaying clarity on future clinical development.
  • Management highlighted the product’s potential benefits based on prior Phase I/II data and differentiation versus competitors but provided no new data or definitive regulatory updates.
  • Operational cash burn is expected at approximately $18 million for Q2 2026, with cash runway into Q1 2027, indicating limited near-term financial flexibility amid regulatory delays.
Full recap
Q2 2025 Aug 13, 2025

Inovio Pharmaceuticals continues to make significant progress toward FDA approval of INO-3107, forecasting a rolling submission for its Biologics License Application (BLA) within the year, supported by compelling efficacy data.

Key takeaways
  • Successful completion of design verification for the CELLECTRA 5PSP device enables next steps in regulatory milestones for INO-3107.
  • The company plans to request a priority review of the BLA, potentially leading to a mid-2026 PDUFA date.
  • Recent data highlight a sustained reduction in surgery rates for RRP patients treated with INO-3107, marking a significant clinical benefit.
  • The FDA inspection of Inovio as the clinical sponsor has been completed successfully, crucial for ongoing regulatory assessments.
  • Inovio is actively pursuing partnerships to advance its next-generation DNA medicine platforms, including dMAb and DPROT technologies.
Full recap